PEPTIDE GUIDE

What Is DSIP?

DSIP stands for delta sleep-inducing peptide. It is a nine-amino-acid peptide first reported in the 1970s after researchers studied substances appearing in the blood of sleeping rabbits.

The name sounds more conclusive than the evidence. “Delta sleep” refers to deep non-rapid-eye-movement sleep associated with slow electrical brain waves. Early experiments suggested that an isolated material could increase this form of sleep, but later research produced inconsistent results and uncertainty about whether free DSIP acts as a normal sleep hormone in people.

Research statusExperimental sleep peptide with small and conflicting human studies
SequenceWAGGDASGE, nine amino acids
Human evidenceSmall, conflicting sleep studies
ApprovalNot an approved medicine
Last reviewedSeptember 2026
THE SHORT ANSWER

DSIP is an experimental nonapeptide, meaning a chain of nine amino acids. Small human studies from the 1980s and 1990s examined intravenous DSIP in insomnia, withdrawal and other settings. Some reported changes in sleep or symptoms, while others found little or no objective improvement. The studies were generally small, used different designs and did not establish a modern treatment programme. DSIP is not an approved sleep medicine, and its identity as a normal circulating human sleep hormone remains uncertain.

What does DSIP stand for?

Delta sleep-inducing peptide describes the setting in which the substance was first investigated. Delta waves are slow, high-amplitude patterns measured by electroencephalography, or EEG. An EEG records electrical activity from electrodes placed on the scalp.

Deep sleep is now usually classified as stage N3 sleep. It forms part of non-rapid-eye-movement sleep, shortened to NREM. Rapid-eye-movement sleep, or REM sleep, is a different stage associated with vivid dreaming and a characteristic pattern of brain and muscle activity.

Calling the molecule sleep-inducing does not mean that every administration reliably causes sleep. Scientific names sometimes preserve an early hypothesis even when later evidence becomes more complicated.

What is DSIP made from?

DSIP has the sequence tryptophan-alanine-glycine-glycine-aspartic acid-alanine-serine-glycine-glutamic acid. Its one-letter sequence is WAGGDASGE.

It is a nonapeptide because it contains nine amino acids joined by peptide bonds. The sequence is not closely related to melatonin, a hormone made by the pineal gland that helps signal biological night. It is also not a benzodiazepine or “Z-drug”, classes of medicines that influence the gamma-aminobutyric acid, or GABA, signalling system.

The relationship between synthetic DSIP and naturally occurring material is unresolved. Researchers have reported DSIP-like immunoreactivity, meaning laboratory antibody signals resembling DSIP, in tissues and fluids. An antibody signal does not always prove that free, intact WAGGDASGE is present. It may also recognise a related sequence within a larger protein.

When was DSIP first documented?

In the 1970s, Swiss researchers studied blood collected from the cerebral circulation of rabbits during electrically induced sleep. They reported isolating a small peptide that appeared to promote slow-wave sleep when transferred to other animals. The sequence later became known as DSIP.

The finding attracted attention because researchers were searching for endogenous sleep substances, meaning compounds naturally produced by the body that help regulate sleep. Work expanded into animal models, biochemical detection and small human studies.

By the 1980s, results were already mixed. Some laboratories reported sleep-related effects, while others struggled to reproduce a consistent response. Human investigations remained small and used intravenous administration, short observation periods and varied patient groups.

PeriodDevelopment
1970sDSIP was isolated and sequenced after rabbit sleep experiments
Early 1980sReviews described animal findings and early human observations, while noting uncertainty about its biological role
1980s and 1990sSmall controlled and uncontrolled human studies examined insomnia, narcolepsy, pain and withdrawal
2000s onwardsDSIP remained a research peptide rather than progressing into a recognised sleep medicine
2026US regulators reviewed compounding nominations and continued to identify major evidence and safety gaps

How is DSIP synthesised and manufactured?

DSIP can be made by solid-phase peptide synthesis. The first protected amino acid is attached to a resin, which is a solid support. Protected amino acids are then added one at a time in reverse sequence until the nine-amino-acid chain is complete.

Protecting groups temporarily cover reactive parts of the amino acids so that each new peptide bond forms in the intended place. Coupling reagents activate one amino acid so it can join the next. The assembled peptide is removed from the resin, its protecting groups are cleared and the crude product is purified.

Preparative liquid chromatography separates intact DSIP from shorter deletion sequences and chemical by-products. Analytical chromatography can estimate purity, while mass spectrometry checks whether the measured molecular mass matches the expected sequence.

Raw materials include protected forms of tryptophan, alanine, glycine, aspartic acid, serine and glutamic acid, together with resin, solvents and coupling reagents. Correct sequence and apparent purity do not establish sterility, endotoxin control, stability or clinical suitability. Those require separate manufacturing controls and validated testing.

How is sleep measured in research?

Sleep research does not rely only on whether someone says they slept better. Polysomnography is an overnight test that records brain waves, eye movements, muscle activity, breathing, oxygen levels and heart rhythm. It can estimate total sleep time, how long it takes to fall asleep and the time spent in each sleep stage.

Sleep efficiency is the percentage of time in bed that is spent asleep. Sleep latency is the time between attempting sleep and falling asleep. Wake after sleep onset measures time awake after first falling asleep.

Subjective measures also matter because insomnia includes dissatisfaction and daytime effects. A person may report better sleep even when an overnight recording changes little. Both types of outcome can be useful, but they answer different questions.

What mechanism has been proposed?

DSIP has been investigated in relation to sleep regulation, stress responses, pain signalling and hormone release. Researchers have reported effects involving the hypothalamus, pituitary gland and several neurotransmitter systems in experimental models.

The hypothalamus is a small brain region involved in sleep, temperature, appetite and hormone control. The pituitary is a gland beneath the brain that releases hormones under hypothalamic direction. A neurotransmitter is a chemical signal used by nerve cells.

No single DSIP receptor has been established in the way that melatonin receptors or opioid receptors have been characterised. Without a clearly defined receptor and reproducible response, it is harder to explain why studies differ or to design a selective medicine.

Some researchers have suggested that DSIP might act indirectly, be produced from a larger precursor protein or modify stress-related systems rather than operating as a simple sleep switch. These remain research ideas, not established clinical mechanisms.

What have animal studies found?

Early animal experiments reported more slow-wave sleep after DSIP administration. Other studies found smaller effects, effects only under certain conditions, or no convincing change. Results varied with species, time of administration, route, prior sleep state and the way sleep was measured.

An animal can also become less active for reasons unrelated to normal restorative sleep. Sedation, illness, stress or altered temperature can reduce movement. EEG measurement is therefore important when a compound is described as sleep-inducing.

Animal studies have also examined pain, stress, seizures and hormone release. These findings broadened the research interest but did not establish a human indication.

What did the human insomnia studies examine?

Small studies enrolled people described as having chronic insomnia or sleep disturbance. Participants generally received DSIP by intravenous infusion or injection under research supervision, sometimes in repeated sessions. A placebo is an inactive comparison designed to resemble the intervention. Random assignment means chance determines which treatment a participant receives.

Some studies reported subjective improvement, more sleep or altered sleep structure. Others did not find a clear benefit over placebo in objective sleep measures. Samples were often small, making results sensitive to individual variation and chance.

The older reports also predate current insomnia trial standards. Modern studies usually define the diagnosis carefully, measure outcomes over longer periods, account for other sleep disorders and report adverse events systematically.

Study design, not dosing guidance

Published human studies used defined intravenous research exposures, often expressed in nanomoles per kilogram or as a measured total amount. A nanomole is one billionth of a mole, a unit that counts molecules. These experiments were conducted with prepared study material and monitoring.

The levels varied between studies and did not establish an approved therapeutic range. They should not be converted into self-administration guidance. Route, infusion conditions, product identity and participant selection all affect exposure and risk.

Why do the human results conflict?

Several factors can produce inconsistent sleep results:

  • very small participant groups;
  • different definitions and causes of insomnia;
  • single-night measurements that are affected by the unfamiliar sleep laboratory;
  • varying routes, timing and exposure levels;
  • incomplete information about product stability;
  • different objective and subjective outcome measures;
  • short follow-up;
  • selective publication of positive findings.

The “first-night effect” is a common change in sleep caused by spending a night connected to equipment in an unfamiliar laboratory. Small studies can mistake this variation for a treatment effect or miss a real but modest effect.

Was DSIP studied in withdrawal?

Small reports examined DSIP during withdrawal from alcohol or opioid drugs. Withdrawal is the group of symptoms that can occur when a person who has become physically dependent reduces or stops a substance.

Some papers described improvements in withdrawal symptoms, sleep or pain. These studies were small and do not support replacing evidence-based withdrawal care. Alcohol and opioid withdrawal can be medically dangerous and may require monitored treatment and established medicines.

Findings in withdrawal also cannot be transferred automatically to ordinary insomnia. The underlying physiology and clinical risks are different.

Was DSIP studied for narcolepsy?

Narcolepsy is a neurological sleep disorder involving excessive daytime sleepiness and, in some people, sudden loss of muscle tone called cataplexy. It is not simply poor sleep at night.

Older work explored whether DSIP altered sleep patterns in narcolepsy. The studies did not establish it as a treatment. Current narcolepsy care is based on a clearer understanding of wake-promoting systems, including the loss of orexin-producing nerve cells in many people with narcolepsy type 1.

Does DSIP improve deep sleep?

There is no dependable modern evidence that a DSIP product predictably increases healthy stage N3 sleep in people. The peptide's name and early animal findings are often presented as though this were established, but controlled human results are inconsistent.

More deep sleep is not automatically better in every context. A useful sleep treatment should improve symptoms and daytime function without unacceptable impairment, breathing problems, dependence or other harms.

Does DSIP affect cortisol or growth hormone?

Some experimental studies reported changes in pituitary or stress-related hormones. Cortisol is a hormone involved in the stress response and daily body rhythms. Growth hormone is released in pulses and often peaks during early sleep.

Sleep itself influences these hormones, so a change after DSIP does not show whether the peptide acted directly on hormone control or indirectly through sleep, stress or study conditions. Small hormone studies do not establish treatment for adrenal, pituitary or growth disorders.

What are the safety concerns?

The human safety database is inadequate. Older small studies cannot reliably detect uncommon adverse events, long-term effects, interactions or risks in pregnancy and chronic disease.

The FDA has identified potential safety concerns for compounded DSIP, including possible immunogenicity and peptide-related impurities. Immunogenicity means the ability to provoke an unwanted immune response. Peptide products can aggregate, meaning several molecules clump together, and aggregation can increase immune risk.

Other uncertainties include how quickly DSIP is broken down, whether its fragments are active and what repeated systemic exposure does. The blood-brain barrier, a selective boundary between blood and brain tissue, may also limit or alter central nervous system exposure.

An unapproved product adds risks of incorrect identity, contamination, strength variation, endotoxin and poor sterility control. Endotoxins are bacterial components that can cause fever and severe inflammatory reactions.

Is DSIP approved?

DSIP is not an FDA-approved or UK-approved medicine for insomnia, anxiety, withdrawal, pain or any other condition.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee considered several nominated substances, including DSIP, for the section 503A bulks list. Section 503A governs certain traditional pharmacy compounding in the United States. Consideration by an advisory committee is not medicine approval, and inclusion or nomination does not demonstrate effectiveness.

An approved medicine has a reviewed formulation, manufacturing process, indication and prescribing information. DSIP does not have that clinical and regulatory package.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Produces deep sleepEarly animal findings and inconsistent small human studies
Treats chronic insomniaNo established modern clinical benefit
Resets the body clockNo dependable evidence for a circadian-rhythm treatment
Reduces anxiety or stressExperimental observations, not an approved clinical use
Treats withdrawalSmall older studies only; not a substitute for medical withdrawal care
Improves recovery by raising growth hormoneNo established clinical evidence
Is a natural human sleep hormoneProposed, but the normal identity and role of free DSIP remain uncertain

How does DSIP differ from melatonin?

Melatonin is a recognised hormone made mainly by the pineal gland at night. Its receptors and role in circadian timing are well characterised. Licensed melatonin medicines exist for specific uses in some countries.

DSIP is a synthetic version of a proposed endogenous nonapeptide with uncertain physiology and no approved sleep indication. Evidence for one should not be transferred to the other.

What research would be needed next?

A credible modern programme would first need a well-characterised product and studies showing how DSIP is absorbed, distributed and broken down. Early clinical work would need careful cardiovascular, neurological, immune and sleep monitoring.

An insomnia trial would need an accepted diagnosis, adequate participant numbers, randomisation, a matched placebo, blinded outcome assessment, polysomnography where appropriate and validated reports of sleep and daytime function. It would also need longer follow-up than a single night.

Why is the natural identity of DSIP uncertain?

Early researchers used biological tests and antibody-based assays to track DSIP-like material. An immunoassay uses an antibody designed to recognise part of a molecule. Antibodies can sometimes bind related sequences, breakdown products or a sequence contained within a larger protein.

Modern confirmation would normally combine separation by chromatography with high-resolution mass spectrometry and sequence analysis. It would also show how concentrations change with natural sleep, sleep deprivation and circadian time.

The difficulty of reproducibly measuring intact DSIP has prevented a clear account of where it is made, how it is released and which receptor receives its signal. Calling it an endogenous sleep hormone therefore goes beyond what has been securely established.

Can DSIP reach the brain?

The blood-brain barrier is formed by tightly connected cells around brain blood vessels. It limits the movement of many substances from blood into brain tissue.

Small peptides may cross in limited amounts, use specialised transport or act through signals outside the barrier. They can also be broken down in blood before reaching the brain. Direct evidence for the human brain exposure of administered DSIP is inadequate.

An effect after intravenous administration does not by itself prove that intact peptide entered the brain. It might alter a peripheral nerve, hormone or immune signal that then affects sleep.

What is known about DSIP breakdown?

Nine-amino-acid peptides are vulnerable to peptidases, enzymes that cut peptide bonds. Breakdown can occur in blood, liver, kidneys and other tissues. A short measured plasma half-life would not necessarily describe how long a downstream biological effect lasts.

Stability also depends on formulation, temperature and acidity. A vial that has degraded may contain a mixture of intact DSIP and fragments. Analytical purity at manufacture does not establish purity at the time of use.

No regulator-reviewed pharmacokinetic profile defines the absorption, distribution, metabolites and removal of a finished DSIP medicine.

How strong is each layer of DSIP evidence?

Evidence layerMain contributionMain limitation
Early isolation experimentsGenerated the hypothesis of a transferable sleep substanceHistorical methods and uncertain molecular identity
Animal sleep studiesTested EEG and behavioural responses in whole organismsMixed replication and species differences
Small human sleep studiesProvided direct human exposure and sleep measurementsSmall groups, varied designs and inconsistent outcomes
Withdrawal and pain reportsExplored other possible usesOften uncontrolled or too small for dependable conclusions
Modern clinical developmentWould establish formulation, benefit and safetyNo established programme

Evidence does not become stronger merely because many possible uses have been studied. A small study in several conditions can create breadth without reliable depth.

Why is insomnia not one simple condition?

Chronic insomnia involves difficulty falling asleep, staying asleep or returning to sleep, together with daytime effects. It can occur alone or alongside depression, anxiety, pain, menopause, medicines, substance use and other sleep disorders.

Obstructive sleep apnoea causes repeated breathing interruptions. Restless legs syndrome creates an urge to move the legs. Circadian-rhythm disorders involve a mismatch between sleep timing and the required schedule. A sedating intervention may mask symptoms without treating the underlying problem.

Modern insomnia trials usually separate these conditions and assess daytime function as well as sleep. Cognitive behavioural therapy for insomnia has a substantial evidence base and works through sleep habits, timing and unhelpful beliefs. DSIP has not been compared with that standard in a robust programme.

What would make a new DSIP trial credible?

The study would need a precisely identified peptide, stability data and a prespecified statistical plan. Participants would have a clearly defined sleep disorder rather than a broad complaint of poor sleep.

Randomisation and a matched placebo would reduce expectation effects. Polysomnography could assess sleep structure, while sleep diaries and validated questionnaires would measure the experience of sleep and daytime functioning.

Repeated-night assessment and follow-up after treatment stops would help separate a treatment effect from ordinary night-to-night variation. Adverse events, next-day impairment and interactions would need systematic reporting.

Why is placebo control especially important in sleep research?

Sleep changes naturally from night to night, and expectations can strongly influence how it is remembered. People often enter a trial during a particularly bad period and improve towards their usual level regardless of treatment. This is called regression to the mean.

A placebo helps estimate these effects. It should resemble the active intervention closely enough that participants cannot easily guess their group. Researchers can ask participants which treatment they thought they received to assess whether blinding worked.

Objective and subjective outcomes should both be reported. An extra few minutes of a sleep stage may not matter if daytime fatigue is unchanged, while a subjective improvement without objective change may still be relevant if it is consistent and durable.

What does sleep architecture mean?

Sleep architecture is the pattern of NREM and REM stages across the night. Healthy sleep usually moves through several cycles rather than remaining in one deep stage.

An intervention that increases one stage could reduce another or cause next-day impairment. Researchers therefore examine total sleep time, awakenings, stage proportions and respiratory measures together.

The name delta sleep-inducing peptide focuses attention on slow-wave sleep. A clinically useful treatment would need to improve the whole sleep problem, not only one EEG band.

Why do withdrawal claims require particular caution?

Alcohol withdrawal can cause seizures and delirium tremens, a severe state involving confusion, agitation and unstable vital signs. Opioid withdrawal is usually less likely to be fatal by itself but can cause dehydration, relapse and overdose risk after tolerance falls.

Small historical DSIP reports do not provide a safe replacement for monitored withdrawal care. Effective treatment depends on the substance, severity, other illness and risk history.

Presenting an experimental peptide as a “detox” aid can delay proven care. It can also hide the difference between reducing one symptom and preventing serious complications.

How should a modern DSIP product be characterised?

Manufacturers would need to confirm the WAGGDASGE sequence, chemical form, water and counter-ion content, purity and degradation products. Injectable products would also require sterility and endotoxin testing.

Stability studies would establish how light, temperature and time affect the finished formulation. Without them, an accurate amount at manufacture may not remain accurate at use.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is DSIP a peptide?

Yes. It is a chain of nine amino acids.

Does DSIP make people sleep?

The results of small human studies are inconsistent. It has not been established as a dependable sleep treatment.

Is DSIP found naturally in the body?

Researchers have reported DSIP-like antibody signals, but the normal existence and role of free intact DSIP remain uncertain.

Is DSIP the same as melatonin?

No. Melatonin is a hormone with established receptors and a recognised role in circadian timing. DSIP is an experimental peptide.

Has DSIP been studied in humans?

Yes, mainly in small older studies involving sleep disorders or withdrawal. These did not establish a modern approved treatment.

Is DSIP FDA approved?

No. It is not an FDA-approved medicine.

What is delta sleep?

It is an older name for deep slow-wave sleep, now generally classified as stage N3 non-rapid-eye-movement sleep.

Are research levels a personal dose?

No. They describe controlled experiments and do not provide treatment instructions.

Research reviewed through September 2026.